Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Russell 2000 ETF (IWM) vs TransMedics Group Inc (TMDX) Price & Performance

iShares Russell 2000 ETFTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs TransMedics Group Inc — how do they compare? iShares Russell 2000 ETF trades at $302.87, while TransMedics Group Inc trades at $87.11 (market cap $3.10B). The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

IWMTMDX
52-Week High
$301.69$150.42
52-Week Low
$225.45$61.99
Market Cap
$3.10B
Sector
Technology
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

IWM (iShares Russell 2000 ETF) trades at $302.71, up 0.91% with a bullish technical signal from moving averages. The ETF, tracking 2,000 US small-cap stocks, shows strong institutional interest despite lacking traditional valuation ratios. Recent news highlights small-cap outperformance versus large caps, with institutional investors favoring IWM for its liquidity and options ecosystem. Technical indicators show RSI at 75 suggesting overbought conditions while ADX indicates a strong trend.

Outlook remains positive as small caps benefit from economic conditions, though high RSI suggests near-term consolidation risk. The ETF's broad small-cap exposure offers diversification but faces volatility from economic sensitivity. Institutional accumulation supports medium-term upside potential despite premium valuation concerns versus alternatives.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX